Jupiter Neurosciences, a clinical-stage pharmaceutical firm, has introduced Nugevia MND, a new cognitive-health supplement that combines its proprietary resveratrol-based JOTROL™ platform with NovaSOL® Curcumin to support brain health, improve cognitive performance, and offer neuroprotective benefits, according to the company. The company said that this pairing targets various neuroprotective pathways—including reducing oxidative stress, lowering inflammation, and supporting synaptic plasticity—to foster enhanced cognitive function.
Jupiter Neurosciences claims the product addresses growing consumer demand for scientifically validated cognitive wellness solutions and opens opportunities in the expanding longevity and wellness market, estimated at US $8 trillion. The company said that Nugevia MND is positioned to generate high-margin revenue by appealing to adults interested in maintaining or improving cognitive performance, especially amid aging populations affected by cognitive decline.
The firm noted that this consumer product complements its pharmaceutical pipeline, with learnings from consumer use—together with biomarker data from its upcoming Phase II Parkinson’s disease trial—expected to guide future cognitive-health initiatives. Jupiter Neurosciences said that Nugevia MND will be available direct-to-consumer through e-commerce platforms beginning Fall 2025, with a convenient two-capsule daily regimen.
